FDA Approves Durvalumab for Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - December 5, 2025 200 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MATTERHORN study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 EMA Recommends Granting a Conditional Marketing Authorisation for Talquetamab August 10, 2023 Our 10 top tips to help you talk about cancer April 24, 2023 Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... December 19, 2023 Load more HOT NEWS Study Finds Accelerated Partial-Breast Radiation Just as Effective as Whole Breast... Coronavirus reports – Part 9: “I am very relieved but I... How Music Can Help You Cope During Cancer: An Expert Perspective “Hero” Nurses Plan Wedding In 24 Hours So Dying Patient Can...
